StockpollyBeta
Get App
Popularity #1,361
ALT · NASDAQ · Biotechnology

Altimmune (ALT)

Developing pemvidutide across MASH, AUD, and alcohol-associated liver disease.

$3.26
vs last close−0.01 (−0.31%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000000000000
Cost of revenue18000000015000
Gross profit−180000000−15000
5342727252522236292426
Research & development181721212020161715181619
5456556661188
General & administrative5456556661188
Other expenses−1812000000−15000
Operating income−23−34−27−27−25−25−22−23−21−29−24−26
222222212223
Interest income222222212235
Interest expense000000000111
Other non-operating income0−2−2−2−2−2−2−1−2−2−30
Income before tax−21−32−24−25−23−23−20−22−19−27−23−23
Income tax expense000000−100000
Net income from continuing operations−21−32−24−25−23−23−20−22−19−27−23−23
Net income−21−32−24−25−23−23−20−22−19−27−23−23
EPS, basic−$0.39−$0.54−$0.34−$0.35−$0.32−$0.33−$0.26−$0.27−$0.21−$0.27−$0.18−$0.12
EPS, diluted−$0.39−$0.54−$0.34−$0.35−$0.32−$0.33−$0.26−$0.27−$0.21−$0.27−$0.18−$0.12
Weighted average shares, basic545871717171768189101124185
Weighted average shares, diluted545871717171768189101124185
EBITDA−22−30−24−25−23−23−20−22−18−26−21−26
Depreciation & amortization020000000000
EBIT−23−32−24−25−23−23−20−22−19−26−21−26